What It Is

LL-37 is a naturally occurring antimicrobial peptide that plays a crucial role in the body’s innate immune system, primarily known for its ability to combat a wide range of pathogens including bacteria, viruses, and fungi by disrupting their membranes. This supports the initial immune defense at sites of injury or inflammation.

LL-37 also promotes tissue healing and recovery by regulating inflammatory responses and facilitating cellular repair, and helps maintain the integrity of barrier tissues such as skin and mucous membranes by stimulating epithelial cell regeneration.

Who May Benefit

• Infection-resistance research
• Wound healing and tissue recovery
• Barrier-tissue integrity research (skin, mucous membranes)
• General innate-immune-function research

What to Expect

LL-37 is generally researched as a consistent protocol over an extended period (the source material describes a 50-day cycle) rather than something with an immediate, dramatic effect.

Because it acts broadly on immune signaling, overstimulation or Herxheimer-type (detox-like) reactions have been reported with improper use — a gradual, conservative approach is preferable.

What to Pair It With

Reconstitution

Suggested Research Dosing Strategy

Administration Notes

Subcutaneous administration in belly fat or thigh, in the morning.

Watch for overstimulation or Herxheimer-type (detox-like) reactions, and reduce the dose if they occur.

Research Considerations

LL-37’s dual role — direct antimicrobial action plus barrier-tissue and healing support — is what distinguishes it from immune-modulating peptides like Thymosin Alpha-1 that work more through coordinating immune cell activity than direct pathogen disruption.

Because it acts on multiple pathways simultaneously, individual response and tolerability should guide dosing more than a fixed escalation schedule.